{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:32Z","timestamp":1788502352162,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the tolerability and efficacy at 3 months of intravenous (IV) allogeneic uterine-derived mesenchymal stromal cells (UMSCs) for osteoarthritis (OA) in client-owned cats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a randomized, masked, placebo-controlled pilot study conducted across six veterinary clinics. Thirty-five client-owned cats with naturally occurring OA were randomly assigned to receive two intravenous injections, given 14 days apart, of one of three treatments: 5 million (5M) UMSCs, 20 million (20M) UMSCs, or saline placebo. Client-Specific Outcome Measures (CSOM), Owner Overall Assessment (OOA), Veterinarian Overall Assessment (VOA) and Veterinarian Pain Assessment (VPA) were recorded at day 0, 14, 30, 60 and 90.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At day 90, predefined treatment success was achieved in: CSOM and OOA for 7\/9(78%) 5M UMSC and 10\/12(83%) 20M UMSC treated cats compared to 4\/11(36.4%) placebo-treated cats for both outcomes; VOA for 4\/8(50%) 5M UMSC and 8\/12(67%) 20M UMSC treated cats compared to 2\/10(20%) placebo-treated cats; and VPA for 6\/8(75%) 5M UMSC and 10\/12(83%) 20M UMSC treated cats compared to 5\/11(45%) placebo-treated cats. Treatment-related adverse events were observed in 1\/10 (10%) 5M UMSC treated cats, 5\/13 (38%) 20M UMSC treated cats, and 2\/12 (16.7%) saline treated cats. The most common treatment related events reported in the first 24 hours were transient vomiting or nausea, weakness, lethargy, hypersalivation, tachypnea and malodorous breath.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study demonstrated that IV administration of allogeneic UMSCs was well tolerated and showed improvement in owner and veterinarian outcomes at both 5M UMSC and 20M UMSC dosing to at least 3 months in cats with naturally occurring OA. Intravenous MSC therapy shows promise for cats with OA and warrants further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fvets.2026.1900571","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:10Z","timestamp":1788499750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pilot study demonstrating safety and efficacy of intravenous allogeneic uterine-derived mesenchymal stromal cell therapy in cats with naturally occurring osteoarthritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Valentine","family":"Williams","sequence":"first","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Mick","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Windsor","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph S.","family":"Parrish","sequence":"additional","affiliation":[{"name":"Vista Research","place":["Bath, ME, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Vista Research","place":["Bath, ME, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Sundman","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Wrightson","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopmanee","family":"Taechangam","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orzala","family":"Sharif","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Black","sequence":"additional","affiliation":[{"name":"Gallant","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cvsm.2023.02.015","article-title":"Feline osteoarthritis management","volume":"53","author":"Deabold","year":"2023","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2460\/javma.2002.220.628","article-title":"Radiographic evidence of degenerative joint disease in geriatric cats: 100 cases (1994\u20131997)","volume":"220","author":"Hardie","year":"1994","journal-title":"J Am Vet Med Assoc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.tvjl.2009.12.014","article-title":"Cross-sectional study of the prevalence and clinical features of osteoarthritis in 100 cats","volume":"187","author":"Slingerland","year":"2011","journal-title":"Vet J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1098612X251347999","DOI":"10.1177\/1098612X251347999","article-title":"Osteoarthritis in cats: what we know, and mostly, what we don\u2019t know\u2026 yet","volume":"27","author":"Lefort-Holguin","year":"2025","journal-title":"J Feline Med Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vetimm.2016.12.007","article-title":"Evaluation of serum cytokines in cats with and without degenerative joint disease and associated pain","volume":"183","author":"Gruen","year":"2017","journal-title":"Vet Immunol Immunopathol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1098612X12470652","article-title":"Feline degenerative joint disease: a genomic and proteomic approach","volume":"15","author":"Gao","year":"2013","journal-title":"J Feline Med Surg"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1501932","DOI":"10.3389\/fpain.2025.1501932","article-title":"Proteomic profiling of serum in cats with naturally occurring degenerative joint disease and co-morbid conditions","volume":"6","author":"Lascelles","year":"2025","journal-title":"Front Pain Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1098612X241241951","DOI":"10.1177\/1098612X241241951","article-title":"2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats","volume":"26","author":"Taylor","year":"2024","journal-title":"J Feline Med Surg"},{"key":"ref9","year":"2026"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"aalag003","DOI":"10.1093\/jvimsj\/aalag003","article-title":"Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration animal drug adverse events database","volume":"40","author":"Lai","year":"2026","journal-title":"J Vet Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"610028","DOI":"10.3389\/fvets.2021.610028","article-title":"Efficacy and safety of an anti-nerve growth factor antibody (frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: a multisite pilot field study","volume":"8","author":"Gruen","year":"2021","journal-title":"Front Vet Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/1098612X14561105","article-title":"Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study","volume":"17","author":"Webb","year":"2015","journal-title":"J Feline Med Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1177\/1098612X221104053","article-title":"Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease","volume":"24","author":"Webb","year":"2022","journal-title":"J Feline Med Surg"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1171922","DOI":"10.3389\/fvets.2023.1171922","article-title":"Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: long term experience","volume":"10","author":"Soltero-Rivera","year":"2023","journal-title":"Front Vet Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1098612X251385852","DOI":"10.1177\/1098612X251385852","article-title":"Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis","volume":"27","author":"Williams","year":"2025","journal-title":"J Feline Med Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/sctm.17-0035","article-title":"Therapeutic efficacy of fresh, allogeneic mesenchymal stem cells for severe refractory feline chronic Gingivostomatitis","volume":"6","author":"Arzi","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1098612X15576980","article-title":"Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats","volume":"18","author":"Quimby","year":"2016","journal-title":"J Feline Med Surg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00418-007-0337-z","article-title":"Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study","volume":"128","author":"Csaki","year":"2007","journal-title":"Histochem Cell Biol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13018-017-0534-y","article-title":"The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review","volume":"12","author":"Goldberg","year":"2017","journal-title":"J Orthop Surg Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/01652176.2019.1643051","article-title":"Animal mesenchymal stem cell research in cartilage regenerative medicine \u2013 a review","volume":"39","author":"Gugjoo","year":"2019","journal-title":"Vet Q"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"982199","DOI":"10.3389\/fcell.2022.982199","article-title":"Updates on mesenchymal stem cell therapies for articular cartilage regeneration in large animal models","volume":"10","author":"Liu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12891-016-1085-9","article-title":"Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy \u2013 a review","volume":"17","author":"Freitag","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.joca.2012.06.003","article-title":"Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture","volume":"20","author":"van Buul","year":"2012","journal-title":"Osteoarthr Cartil"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.2460\/javma.24.02.0074","article-title":"Scoping review of the use of mesenchymal stem and stromal cell products in cats, part 1: current logistics and safety","volume":"262","author":"Webb","year":"2024","journal-title":"J Am Vet Med Assoc"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"105470","DOI":"10.1016\/j.rvsc.2024.105470","article-title":"Evaluation of the quality of life-enhancing effect of allogeneic feline adipose mesenchymal stem cells in cats with osteoarthritis: a pilot study","volume":"182","author":"Mitani","year":"2025","journal-title":"Res Vet Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/scd.2022.0296","article-title":"Intravenous injection of equine mesenchymal stem cells in dogs with articular pain and lameness: a feasibility study","volume":"32","author":"Brondeel","year":"2023","journal-title":"Stem Cells Dev"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-023-03168-7","article-title":"Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing","volume":"25","author":"Beerts","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-0039-1678547","article-title":"Evaluation of intravenously delivered allogeneic mesenchymal stem cells for treatment of elbow osteoarthritis in dogs: a pilot study","volume":"32","author":"Olsen","year":"2019","journal-title":"Vet Comp Orthop Traumatol"},{"key":"ref29","year":""},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/javma.22.11.0515","article-title":"Perspectives on implementing veterinary clinical studies committees","volume":"261","author":"Baneux","year":"2023","journal-title":"JAVMA"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2460\/ajvr.80.8.743","article-title":"Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats","volume":"80","author":"Khelik","year":"2019","journal-title":"Am J Vet Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-3164.2004.00410_2-6.x","article-title":"Bioavailability and activity of prednisone and prednisolone in the feline patient","volume":"15","author":"Graham-Mize","year":"2004","journal-title":"Vet Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1939-1676.2007.tb02983.x","article-title":"Evaluation of client-specific outcome measures and activity monitoring to measure pain relief in cats with osteoarthritis","volume":"21","author":"Lascelles","year":"2007","journal-title":"J Vet Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e0131839","DOI":"10.1371\/journal.pone.0131839","article-title":"Criterion validation testing of clinical metrology instruments for measuring degenerative joint disease associated mobility impairment in cats","volume":"10","author":"Gruen","year":"2015","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/jvim.16291","article-title":"Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats","volume":"35","author":"Gruen","year":"2021","journal-title":"J Vet Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1746-6148-8-10","article-title":"Relationship of orthopedic examination, goniometric measurements, and radiographic signs of degenerative joint disease in cats","volume":"8","author":"Lascelles","year":"2012","journal-title":"BMC Vet Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/1098612X15604351","article-title":"Intravenous adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study","volume":"18","author":"Trzil","year":"2016","journal-title":"J Feline Med Surg"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1532-950X.2010.00708.x","article-title":"Cross-sectional study of the prevalence of radiographic degenerative joint disease in domesticated cats: degenerative joint disease in domestic cats","volume":"39","author":"Lascelles","year":"2010","journal-title":"Vet Surg"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1177\/1098612X20907424","article-title":"Development of a checklist for the detection of degenerative joint disease-associated pain in cats","volume":"22","author":"Enomoto","year":"2020","journal-title":"J Feline Med Surg"},{"key":"ref40","first-page":"890704","article-title":"High Molecular Weight Hyaluronic Acid in Dogs With Osteoarthritis: Exploratory Data From a Double-Blind, Randomized, Prospective Clinical Trial","volume-title":"Front Vet Sci","author":"Kim","year":"2022"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1035175","DOI":"10.3389\/fvets.2022.1035175","article-title":"Homing of radiolabelled xenogeneic equine peripheral blood-derived MSCs towards a joint lesion in a dog","volume":"9","author":"Beerts","year":"2022","journal-title":"Front Vet Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1098612X11432828","article-title":"Osteoarthritis in the cat: 1. How common is it and how easy to recognise?","volume":"14","author":"Bennett","year":"2012","journal-title":"J Feline Med Surg"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/scrt198","article-title":"Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies","volume":"4","author":"Quimby","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/cea.12411","article-title":"Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma","volume":"44","author":"Trzil","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1098612X261431058","DOI":"10.1177\/1098612X261431058","article-title":"EXPRESS: a long-term field safety study evaluating allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis (FCGS)","volume":"28","author":"Williams","year":"2026","journal-title":"J Feline Med Surg"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1098612X18758590","article-title":"Mesenchymal stem cell therapy in cats: current knowledge and future potential","volume":"20","author":"Quimby","year":"2018","journal-title":"J Feline Med Surg"},{"key":"ref47","volume-title":"Information about the Boxed Warning on Meloxicam Labels Regarding Safety Risks in Cats","year":"2024"},{"key":"ref48","volume-title":"Adverse Drug Event (ADE) Database FOIA Response for Solensia (Frunevetmab)","year":"2024"},{"key":"ref49","volume-title":"Get the Facts about Pain Relievers for Pets","year":"2022"},{"key":"ref50","year":"2022"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.2460\/javma.24.02.0080","article-title":"Scoping review of the use of mesenchymal stem and stromal cell products in cats, part 2: current scope and efficacy","volume":"262","author":"Webb","year":"2024","journal-title":"J Am Vet Med Assoc"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/vr.104168","article-title":"Caregiver placebo effect in analgesic clinical trials for cats with naturally occurring degenerative joint disease-associated pain","volume":"180","author":"Gruen","year":"2017","journal-title":"Vet Rec"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jot.2025.08.009","article-title":"Immunoregulatory orchestrations in osteoarthritis and mesenchymal stromal cells for therapy","volume":"55","author":"Jiang","year":"2025","journal-title":"J Orthop Translat"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"10384","DOI":"10.3390\/ijms231810384","article-title":"A 2022 systematic review and Meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis","volume":"23","author":"Barbeau-Gr\u00e9goire","year":"2022","journal-title":"IJMS"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1621296","DOI":"10.3389\/fvets.2025.1621296","article-title":"Evidence of osteoarthritis disease modification with a Sn-117m microparticle device: a review and validation in mammalian models","volume":"12","author":"Bendele","year":"2025","journal-title":"Front Vet Sci"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1900571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:12Z","timestamp":1788499752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1900571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":55,"alternative-id":["10.3389\/fvets.2026.1900571"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1900571","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1900571"}}